06.10.2023 Bank of America Securities Europe SA  DE000A3ENQ51

EQS-News: Bank of America Securities Europe SA: Exercise of the Greenshoe Option and Post-stabilisation Period Announcement


 

EQS-News: Bank of America Securities Europe SA / Key word(s): IPO
Bank of America Securities Europe SA: Exercise of the Greenshoe Option and Post-stabilisation Period Announcement

06.10.2023 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

6 October 2023

 

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

 

SCHOTT Pharma AG & Co. KGaA

 

Exercise of the Greenshoe Option and Post-stabilisation Period Announcement

 

Further to the pre-stabilisation period announcement dated 27 September 2023, BofA Securities Europe SA (contact: Victor Dumas Vorzet; telephone: +33187701048) hereby gives notice that the Stabilisation Manager named below has fully exercised the over-allotment/greenshoe option (of up to 4,518,438 shares) on 6 October 2023 in respect of 4,518,438 shares at the offer price of EUR 27.00 per share and that the stabilisation period has been concluded early on 6 October 2023. During the stabilisation period, the Stabilisation Manager did not undertake stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/2016/2014), and also as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) in relation to the offer of the following securities, as set out below.

 

Issuer: SCHOTT Pharma AG & Co. KGaA (“SCHOTT Pharma“)
Description: -Offering of existing ordinary bearer shares with no par value of SCHOTT Pharma
-ISIN: DE000A3ENQ51
-WKN: A3ENQ5
-Ticker: 1SXP
Offer size: 30,122,924 shares (excluding the over-allotment option)
Stabilisation Manager: BofA Securities Europe SA, 51 rue la Boétie, 75008 Paris
Offer price: EUR 27.00
Stabilisation started: 28 September 2023

 

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement is not an offer of securities for sale into the United States. The securities referred to above have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There has not been and will not be a public offer of the securities in the United States.

 



06.10.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


1742835  06.10.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1742835&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 0,00 0,00 0,00 584,23 648,67 821,14 898,60
EBITDA1,2 0,00 0,00 0,00 131,94 164,10 219,73 239,00
EBITDA-Marge3 0,00 0,00 0,00 22,58 25,30 26,76
EBIT1,4 0,00 0,00 0,00 98,22 127,66 164,38 192,38
EBIT-Marge5 0,00 0,00 0,00 16,81 19,68 20,02 21,41
Jahresüberschuss1 0,00 0,00 0,00 77,63 101,17 125,85 151,93
Netto-Marge6 0,00 0,00 0,00 13,29 15,60 15,33 16,91
Cashflow1,7 0,00 0,00 0,00 104,40 132,21 182,12 181,65
Ergebnis je Aktie8 0,00 0,00 0,00 0,51 0,67 0,83 1,01
Dividende8 0,00 0,00 0,00 0,00 0,00 0,12 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ernst & Young

INVESTOR-INFORMATIONEN
©boersengefluester.de
Schott Pharma
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A3ENQ5 38,700 5.828,79
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
31,21 23,77 1,29 45,96
KBV KCV KUV EV/EBITDA
8,73 32,09 6,49 25,01
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,12 0,15 0,39 14.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
29.02.2024 27.06.2024 29.08.2024 26.01.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-0,56% 0,00% 15,18% 0,00%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Bank of America Securities Europe SA  ISIN: DE000A3ENQ51 können Sie bei EQS abrufen


Oberflächen/Verpackung , A3ENQ5 , 1SXP , XETR:1SXP